Japan· JP-3959422A1028
セルリポナーゼ アルファ（遺伝子組換え）
A medicinal product containing セルリポナーゼ アルファ（遺伝子組換え）, registered in Japan by ＢｉｏＭａｒｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｊａｐａｎ, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- セルリポナーゼ アルファ（遺伝子組換え）
- Manufacturer
- ＢｉｏＭａｒｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｊａｐａｎ
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
セルリポナーゼ アルファ（遺伝子組換え） in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumBrineura 150 mgBioMarin International
- CanadaBRINEURABIOMARIN INTERNATIONAL LIMITED
- CzechiaBRINEURABioMarin International Limited, Dublin
- SpainBRINEURA 150 MG SOLUCION PARA PERFUSIONBiomarin International Limited
- FinlandBrineuraBiomarin International Limited
- FranceBRINEURA 150 mg, solution pour perfusionBIOMARIN INTERNATIONAL LIMITED (IRLANDE)
- United KingdomBrineura 150mg/5ml solution for infusion vialsBioMarin (U.K.) Ltd
- IrelandBrineura 150 mg solution for infusionBioMarin International Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Brineura
- Liechtenstein · Brineura
- Norway · Brineura
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/58f2633a-b58f-4a02-b46a-82c0375ad5a2 GET /v1/drugs/58f2633a-b58f-4a02-b46a-82c0375ad5a2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１５０ｍｇ５ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3959422A1028",
"category": "注射薬",
"price_yen": 1327645,
"generic_name": "セルリポナーゼ アルファ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "3959",
"transitional_expiry": null
}See everything about セルリポナーゼ アルファ（遺伝子組換え）.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.